Circassia Pharmaceuticals, Inc., a specialty pharmaceutical company focused on respiratory disease, is pleased to announce that Aetna, one of the largest health insurance companies in the United States, has updated its Exhaled Breath Tests Clinical Policy to include the measurement of exhaled nitric oxide as “medically necessary” for the evaluation of asthma and for monitoring the response to long-term control therapy.
Asthma is a chronic disease that causes your airways to be inflamed. The most common symptoms of asthma are coughing, shortness of breath, wheezing and chest tightness. But there are other diseases that can have the same symptoms of asthma. For your doctor to make the right diagnosis, it is important to know if your airways are inflamed.
Circassia Pharmaceuticals, Inc. (“Circassia” or “the Company”), a specialty pharmaceutical company focused on respiratory disease, today announced that Fractional Exhaled Nitric Oxide (FeNO) monitoring is recommended in the latest Global Initiative for Asthma (GINA) guide, “Difficult-to-Treat & Severe Asthma in Adolescent and Adult Patients – Diagnosis and Management.”
On Dec. 3, 2020, the National Institutes of Health (NIH) announced updates to the clinical guidelines used to diagnose and manage asthma. The new guidelines are titled "The 2020 Focused Updates to the Asthma Management Guidelines: A Report from The National Asthma Education and Prevention Program Expert Panel Working Group." The National Heart, Lung, and Blood Institute (NHLBI), part of the NIH, oversaw the National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC) and...
When you block a person, they can no longer invite you to a private message or post to your profile wall. Replies and comments they make will be collapsed/hidden by default. Finally, you'll never receive email notifications about content they create or likes they designate for your content.
Note: if you proceed, you will no longer be following .